SCHEMBL4167261

SCHEMBL4167261

Cc1cc(N2CCOCC2)ccc1NC(=N)N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
MAPT P10636 4/20 0.47
ALDH1A1 P00352 2/20 0.47
TP53 P04637 2/20 0.47
MAPK1 P28482 2/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
RAB9A P51151 2/20 0.47
GAA P10253 1/20 0.47
POLB P06746 1/20 0.45
TTK P33981 1/20 0.45
HPGD P15428 2/20 0.44
LGMN Q99538 1/20 0.44
ATM Q13315 1/20 0.44
TNIK Q9UKE5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1592539 0.77 MAPT (0.58) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL4172379 0.75 MAPT (0.50) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL2260066 0.75 GAA (0.49) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL1911932 0.74 MAPT (0.69) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL27539408 0.74 IGF1R (0.55) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL3230406 0.74 PRKDC (0.58) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL78755 0.73 LGMN (0.67) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL1911977 0.73 PRKDC (0.58) MEN1KMT2AMAPTALDH1A1TP53
SCHEMBL4173591 0.73 MAPT (0.47) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL4161854 0.73 MAPT (0.45) MEN1KMT2AMAPTALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 MEN1 2980/4885KMT2A 1239/4885MAPT 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.